New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

July 2017

Welcome to the July 2017 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the July issue!

The PharmSource Team


Contacts Are Where It’s At

by Brooke Wilson, Senior Research Analyst

The true purpose of the PharmSource Lead Sheet is to keep you abreast of any event that would create an opportunity for a service or product provider in the drug, device or diagnostic development arena.

In order to create this weekly business development tool we track drugs from discovery through to marketed, alert you to bio/pharma companies that have raised funds, then detail how they plan to use the money, and break down product deals and acquisitions. What do you need most now that you are armed with this new information? Verified contacts… read on

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type June 2017 YTD 2017
Early Development 135 671
Late Development 132 665
Biologic 121 630
Small Molecule 266 1474
Parenteral 121 675
Oral 109 569
New Financings 78 491
Total Drug Leads 382 2187
Total Device &
Diagnostic Leads
133 857

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

Almac Discovery receives FDA orphan drug designation for ALM-201 for the treatment of ovarian cancer:

  • Therapeutic Area: Oncology – Other
  • Dosage Form: Parenteral
  • API: Peptide – Process unknown non-cyto

Get deeper information about the likely upcoming needs of Almac Discovery, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on AveXis, Inc.

AveXis, Inc. develops gene therapies for the treatment of rare and orphan neurological genetic diseases. They plan to raise $234.5 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to fund general corporate purposes, including manufacturing, R&D activities and ongoing clinical trials of its pipeline, which may include… read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on Titan Medical, Inc.

Titan Medical, Inc. is a public company based in Canada that designs and develops robotic surgical systems for applications in minimally invasive surgery. They plan to raise $17.3 million in the completion of a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support the development of their SPORT Surgical System… read on

Dose CMOs Stuck in Idle

PharmSource’s just-released trend report, Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition, reveals several factors for the dose CMO industry’s relatively poor performance in 2016:

1. Rebound in drug development since 2013 is too recent to benefit dose CMOs

2. Heavy investment in captive capacity by global bio/pharma companies

3. Declining significance of dose manufacturing in drug cost of goods as new drugs with high value APIs dominate the pipeline


PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).